Caitong International Asset Management’s Crescent Biopharma CBIO Stock Holding History

Caitong International Asset Management’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$73	Buy	+4	New	+$46	﹤0.01%	1989

Other funds holding CBIO

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Balyasny Asset Management

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Caitong International Asset Management's CBIO Position: Q1 2026 in Review

Caitong International Asset Management opened a new position in Crescent Biopharma (CBIO) in Q1 2026: 4 shares worth $73. The stake represents ﹤0.01% of the portfolio and ranks #1989 among its holdings.

63 funds tracked by Wall St. Rank hold CBIO as of Q1 2026.

Caitong International Asset Management held 4 shares of Crescent Biopharma worth $73 as of Q1 2026.
Crescent Biopharma was a new Caitong International Asset Management position in Q1 2026.
Crescent Biopharma made up ﹤0.01% of Caitong International Asset Management's portfolio in Q1 2026, its #1989 holding.
63 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.